Fig. 7

Antitumor immunity in vivo. Flow cytometry analysis of A) CD11c+CD80+ cells and B) CD11c+CD86+ cells in the spleens of mice bearing primary tumor and bone metastases in different groups. C) Flow cytometry analysis of CD80+CD86+ cells in the lymph nodes. D) Flow cytometry analysis of CTLs and E) the ratio of CTL/Treg cells in primary tumors. F) Fluorescence imaging in vitro and corresponding G) semiquantitative fluorescence analysis of lymph nodes in different groups. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)